Evaluation of Subretinal fluid Drainage Techniques During Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment – ELLIPSOID Study

January 2023 Written by:  Priya Vakharia, MD Retina Vitreous Associates of Florida Tampa Bay, FL McKay BR, Bansal A, Kryshtalskyj M, Wong DT, Berger A, Muni RH. Evaluation of Subretinal fluid Drainage Techniques During Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment-ELLIPSOID Study. Am J Ophthalmol. 2022 Sep;241:227-237. doi: 10.1016/j.ajo.2022.05.008. Epub 2022 May 18. PMID: 35597323. This […]

Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial

December 2022 Written by:  Jordan Deaner, MD Mid Atlantic Retina / Wills Eye Hospital Philadelphia, PA Rush RB, Velazquez JC, Rosales CR, Rush SW. Gas Tamponade for the Prevention of Postoperative Vitreous Hemorrhaging After Diabetic Vitrectomy: A Randomized Clinical Trial. Am J Ophthalmol. 2022;242:173-180. doi:10.1016/j.ajo.2022.06.015 Disclosures: EyePoint – Consultant, Alimera – Consultant Vitreous hemorrhage (VH) […]

Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration

December 2022 Written by:  Jordan Deaner, MD Mid Atlantic Retina / Wills Eye Hospital Philadelphia, PA Holz FG, Oleksy P, Ricci F, et al. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54-63.   Recently the United States Food and Drug Administration (USFDA) approved the first interchangeable biosimilar for use […]

OCT Risk Factors for Development of Atrophy in Eyes with Intermediate Age-Related Macular Degeneration

November 2022 Written by:  Katherine E. Talcott, MD Cole Eye Institute / Cleveland Clinic Hirabayashi K, Yu HJ, Wakatsuki Y, Marion KM, Wykoff CC, Sadda SR. OCT risk factors for development of atrophy in eyes with intermediate age-related macular degeneration. Ophthalmol Retina. 2022;6;S2468-6530(22)00486-9. doi 10.1016/j.oret.2022.09.007. Online ahead of print. While treatments for atrophic age-related macular […]

Embedding Technique versus Conventional Internal Limiting Membrane Peeling for Lamellar Macular Hole with Epiretinal Proliferation

August 2022 Written by:  Nika Bagheri, MD California Retina Consultants Santa Barbara, CA Kanai M., Sakimoto S., Takahashi S., Nishida K., Maruyama K., Sato S., Sakaguchi H. & Nishida K., Embedding Technique versus Conventional Internal Limiting Membrane Peeling for Lamellar Macular Hole with Epiretinal Proliferation, Ophthalmology Retina (2022), doi: https:// doi.org/10.1016/j.oret.2022.07.009.  The purpose of this […]

Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy

June 2022 Written by:  Wenlan Zhang, MD Retina Northwest Portland, OR Patel, N. Yannuzzi, N. Lin, J. Smiddy, W. A Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy. Ophthalmol Retina. 2022;6:213-218. This was a cost-effectiveness analysis based on published data from two recent randomized control trials studying the early treatment of […]

Postoperative Endophthalmitis in Immediate Sequential Bilateral Cataract Surgery

May 2022 Written by: Phillip Storey, MD Austin Retina Associates Austin, TX Friling E, Johansson B, Londsteom M, et al. Postoperative endophthalmitis in immediate sequential bilateral cataract surgery: a nationwide registry study.Ophthalmology. 2022;129(1):26-34. Lacy M, Kung T, Owens J, et al. Endophthalmitis rate in immediately sequential versus delayed sequential bilateral cataract surgery within the IRIS registry […]

Faricimab and DME: YOSEMITE and RHINE (Phase 3 Trial)

May 2022 Written by: Edward Wood, MD Austin Retina Associates Austin, TX Wykoff, C. C., F. Abreu, A. P. Adamis, and K. Basu. 2022. “Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials. The Lancet. […]